FORT COLLINS – A biopharmaceutical company that works out of a facility at Colorado State University is preparing to demonstrate the effectiveness of one of its vaccines next week in the nation’s capital.
Vivaldi Biosciences, a clinical-stage biotechnology company developing nasal spray vaccines for viral respiratory diseases, will present data on its DeltaFLU universal influenza vaccine on April 5 at the World Vaccine Congress in Washington.
Thomas Muster, Vivaldi’s chief scientific officer, will present data showing the success of its vaccine against influenza virus type A and B strains. These proof-of-concept data from preclinical challenge studies indicate the potential for DeltaFLU to protect against all influenza strain types causing seasonal and pandemic influenza in humans, the company said in a prepared statement issued Wednesday.
A venture capital-backed company, Vivaldi Biosciences has operations at the Research Innovation Center at CSU in Fort Collins as well as in Vienna, Austria. NGN Capital LLC is the company’s lead investor.
Vivaldi Biosciences is preparing for a Phase 2 clinical challenge study to demonstrate efficacy and the potential for universal protection with the vaccine. The randomized, placebo-controlled challenge study will evaluate protection provided by DeltaFLU in healthy adult volunteers in a controlled setting. Clinical challenge studies can indicate efficacy faster and with a smaller number of subjects than conventional Phase 3 studies.
DeltaFLU is a nasal spray vaccine with what the company calls “a unique mode of action. DeltaFLU rapidly induces interferon and broadly cross-neutralizing mucosal antibodies in the nasal passages, creating a first line of defense at the point of entry of circulating viruses. The self-adjuvanting effect of interferon enhances T- and B-cell activity for a broadly protective systemic immune response, with cross-protective serum antibodies directed to conserved regions of the influenza hemagglutinin antigen.”
Vivaldi’s Delta-19 combination vaccine for COVID-19 and influenza is in preclinical development.